Droupadi Murmu, the President of India, inaugurated the nation’s first indigenous cancer gene therapy at the renowned Indian Institute of Technology (IIT) in Bombay on Thursday, April 4. This innovative treatment, known as “CAR-T cell therapy,” is both affordable and readily available, offering a beacon of hope for humanity, according to an official statement from the President’s office.
During her speech, President Murmu emphasized that this indigenous gene therapy signifies a significant milestone in India’s ongoing fight against cancer. She was informed that this therapy would be offered in major cancer hospitals nationwide, bringing renewed optimism to patients and their loved ones. Furthermore, she stated that this cost-effective treatment could be extended to patients globally, aligning with the philosophy of “Vasudhaiva Kutumbakam.”
CAR-T cell therapy, also known as chimeric antigen receptor T-cell therapy, is a combination of immunotherapy and gene therapy. It involves intricate genetic engineering to alter a patient’s immune cells, particularly T cells, to combat cancer. President Murmu described CAR-T cell therapy as one of the most remarkable advancements in medical science.
She underscored that this therapy is the most cost-effective CAR-T cell therapy worldwide. It also exemplifies the “Make in India” initiative of the Modi government and is a shining testament to “Atmanirbhar Bharat” (self-reliant India).
The development of CAR-T cell therapy is a collaborative effort between IIT Bombay, Tata Memorial Hospital, and industry partner ImmunoACT. The President’s office stated in a release that this endeavor not only utilizes technology for the betterment of humanity but also fosters partnerships with distinguished institutions from various fields and the industry.
You might also be interested in – Delhi Gang Sells Rs. 100 Fungus Medicine for Rs. 2 Lakh as Cancer Injections
